|
|
CARP-1 |
|
Vaxjo ID |
491 |
|
Vaccine Adjuvant Name |
CARP-1 |
|
Adjuvant VO ID |
VO_0005768
|
|
Description |
TLR4 polysaccharide adjuvant from cultivated Artemisia rupestris L that induces Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
China |
|
Host Species for Testing |
Mouse |
|
Components |
77.1% neutral sugars, 7.2% proteins, 7.2% uronic acid |
|
Structure |
heteropolysaccharide composed of galactose, arabinose, glucose, rhamnose and galacturonic acid in the molar ratio of 1:0.9:0.48:0.31:0.05 |
|
Molecular Weight |
27.2 kDa |
|
Preparation |
A. rupestris L. powder was water-extracted, ethanol-precipitated, deproteinized, dialyzed to obtain crude polysaccharide |
|
Function |
Type: plant-derived vaccine adjuvant. Induces Th1-biased immune profile. CARP-1 stimulates the immune response by engaging the TLR4 pathway, triggering the activation of NF-?B and MAPK pathways and upregulating CD40 and CD86, This activation leads to the production of pro-inflammatory cytokines, including TNF-? and IL-6, which in turn activate dendritic cells and other innate immune cells, ultimately shaping the adaptive response. The production of TNF-? and IL-6 also promotes the activation of T cells |
| References |
Li et al., 2022: Li Q, Weng X, Zhao B, Yang Y, Zhang A. Immunoregulatory properties of the cultivated Artemisia rupestris L. polysaccharide as a potential adjuvant. Carbohydrate polymers. 2022; 291; 119525. [PubMed: 35698367].
|
|
